Spots Global Cancer Trial Database for A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
Official Title: A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules as First-line Treatment for Advanced Hepatocellular Carcinoma.
Study ID: NCT05975645
Conditions
Study Description
Brief Summary: This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and Anlotinib Hydrochloride Capsules in patients with advanced HCC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Gansu Wuwei Cancer Hospital, Wuwei, Gansu, China
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Affiliated hospital of zunyi medical university, Zunyi, Guizhou, China
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
The First People's Hospital of Shangqiu City, Shangqiu, Henan, China
Hunan Cancer Hospital, Changsha, Hunan, China
The six people's Hospital of Shenyang, Shenyang, Liaoning, China
Third Affiliated Hospital of Naval Medical University, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
